{"blog": [], "keywords": [{"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "1", "is_major": "N"}, {"value": "Biotechnology and Bioengineering", "name": "subject", "rank": "2", "is_major": "N"}, {"value": "Health Insurance and Managed Care", "name": "subject", "rank": "3", "is_major": "N"}, {"value": "Biotechnology Industry Organization", "name": "organizations", "rank": "4", "is_major": "N"}], "web_url": "http://www.nytimes.com/2015/05/12/opinion/cost-barrier-to-medicines.html", "document_type": "article", "byline": [], "type_of_material": "Letter", "multimedia": [], "section_name": "Opinion", "word_count": "189", "source": "The New York Times", "subsection_name": null, "lead_paragraph": "Jim Greenwood of the Biotechnology Industry Organization calls for an examination of &#8220;the insurance industry&#8217;s recent expansion of the use of specialty tier cost-sharing, in which patients must pay a relatively high percentage of their drug costs.&#8221;", "pub_date": "2015-05-12T00:00:00Z", "news_desk": "Letters", "headline": {"kicker": "Letter", "print_headline": "Cost Barrier to Medicines", "main": "Cost Barrier to Medicines", "content_kicker": "Letter"}, "print_page": "22", "snippet": "Jim Greenwood of the Biotechnology Industry Organization calls for an examination of &#8220;the insurance industry&#8217;s recent expansion of the use of specialty tier cost-sharing, in which patients must pay a relatively high percentage of their...", "_id": "5551a9e438f0d84851b12dce", "slideshow_credits": null, "abstract": null}